Evidence map›Paper›PMID 26463234›Full record

ArticleThe British journal of radiology2015

Dosimetric benefits of hemigland stereotactic body radiotherapy for prostate cancer: implications for focal therapy.

Amar U Kishan, Sang J Park, Christopher R King, Kristofer Roberts, Patrick A Kupelian, Michael L Steinberg, Mitchell Kamrava

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The British journal of radiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Amar U KishanDepartment of Radiation Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA.
Sang J ParkDepartment of Radiation Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA.
Christopher R KingDepartment of Radiation Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA.
Kristofer RobertsDepartment of Radiation Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA.
Patrick A KupelianDepartment of Radiation Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA.
Michael L SteinbergDepartment of Radiation Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA.
Mitchell KamravaDepartment of Radiation Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA.
University of California, Los Angeles · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveCompared with standard, whole-gland (WG) therapies for prostate cancer, focal approaches may provide equivalent oncologic outcomes with fewer adverse effects. The purpose of this study was to compare organ-at-risk (OAR) dosimetry between hemigland (HG) and WG stereotactic body radiotherapy (SBRT) plans.

methodsVolumetric-modulated arc radiotherapy-based SBRT plans were designed to treat the left HG, right HG and WG in eight patients, using five fractions of 8 Gy. OARs of interest included the contralateral HG, rectum, urinary bladder, urethra, penile bulb and contralateral neurovascular bundle.

resultsRectal V80% (the percentage of a normal structure receiving a dose of 80%) and V90% were significantly lower with HG plans than with WG plans (median values of 4.4 vs 2.5 cm(3) and 2.1 vs 1.1 cm(3), respectively, p < 0.05 by Student's t-test). Bladder V50% was also reduced significantly in HG plans (32.3 vs 17.4 cm(3), p < 0.05), with a trend towards reduction of V100% (3.4 vs 1.3 cm(3), p = 0.09). Urethral maximum dose and mean doses to the penile bulb and contralateral neurovascular bundle were also reduced significantly (42.0 vs 39.7 Gy, p < 0.00001; 13.3 vs 9.2 Gy, p < 0.05; and 40.2 vs 19.3 Gy, p < 0.00001, respectively).

conclusionTargeting an HG volume rather than a WG volume when delivering SBRT can offer statistically significant reductions for all OARs. Given the large magnitude of the reduction in dose to these OARs, it is anticipated that HG SBRT could offer a superior toxicity profile when compared with WG SBRT. This is likely to be most relevant in the context of salvaging a local failure after radiation therapy. ADVANCES IN KNOWLEDGE: The dosimetric feasibility of HG SBRT is demonstrated. When compared with WG SBRT plans, the HG plans demonstrate statistically significant and large magnitude reduction in doses to the rectum, bladder, urethra, penile bulb and contralateral neurovascular bundle, suggesting the possibility of improved toxicity outcomes with HG SBRT. This is likely to be most relevant in the context of salvaging a local failure after radiation therapy.

Indexed as

HumansMaleOrgans at RiskPenisProstateProstatic NeoplasmsRadiotherapy DosageRadiotherapy, Intensity-ModulatedRadiotherapy Planning, Computer-AssistedRectumUrethraUrinary Bladder

Identifiers

PMID26463234
PMCPMC4984947
OpenAlexW1955226607

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.